Zobrazeno 1 - 10
of 13
pro vyhledávání: '"ANEZKA ZEMANKOVA"'
Autor:
Anezka Zemankova, Hana Studentova, Andrea Kopova, Tomas Tichy, Vladimir Student, Bohuslav Melichar
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionNeoadjuvant nivolumab and cabozantinib in locally advanced renal cell carcinoma in a horseshoe kidney is a novel therapeutic approach in the preoperative setting.MethodsWe report a case of a 52-year old male who presented with a large ino
Externí odkaz:
https://doaj.org/article/36ccf721adff4bf8984088bc2a954c94
Autor:
Hana Studentova, Nikol Rusarova, Andrea Ondruskova, Anezka Zemankova, Vladimir Student, Daniela Skanderova, Bohuslav Melichar
Publikováno v:
Current Oncology, Vol 29, Iss 8, Pp 5475-5488 (2022)
Background: Renal cell carcinoma with sarcomatoid dedifferentiation represents a rare histological entity characterized by aggressive behavior, limited efficacy of tyrosine kinase inhibitors or mTOR inhibitors, and poor outcome. The immune checkpoint
Externí odkaz:
https://doaj.org/article/24bc403beb2948da91071fefa7058f66
Autor:
Igor Richter, Alexandr Poprach, Anezka Zemankova, Tomas Buchler, Jiri Bartos, Vladimir Samal, Hana Studentova, Aneta Rozsypalova, Josef Dvorak, Ondrej Brom, Bohuslav Melichar
Publikováno v:
Biomedical Papers, Vol 166, Iss 1, Pp 97-104 (2022)
Aim. The aim of this study was to retrospectively analyze treatment outcomes and tolerance in patients in whom cabozantinib was used after previous targeted therapy. Patients and Methods. Cabozantinib was administered in dose 60 mg/day, a subset of p
Externí odkaz:
https://doaj.org/article/15cacfbb56434393aa47bcaf504f7acd
Autor:
Hana Studentova, Jindriska Volakova, Martina Spisarova, Anezka Zemankova, Kvetoslava Aiglova, Tomas Szotkowski, Bohuslav Melichar
Publikováno v:
BMC Gastroenterology, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Sunitinib and pazopanib are both oral small molecule multityrosine kinase inhibitors (MTKI) used in the treatment of renal cell carcinoma (RCC). Hepatotoxicity or “liver injury” is the most important adverse effect of pazopani
Externí odkaz:
https://doaj.org/article/0d1fca5cc18a4a52b0ed320697e74d14
Autor:
Hana Studentova, Anezka Zemankova, Martina Spisarova, Daniela Skanderova, Zbynek Tudos, Bohuslav Melichar, Vladimir Student
Publikováno v:
Medicina, Vol 58, Iss 3, p 336 (2022)
Background and Objectives: Complete pathological response after ipilimumab and nivolumab combination therapy in a patient with intermediate prognosis renal cell carcinoma is an uncommon finding. Case presentation: A 60-year-old man presented with syn
Externí odkaz:
https://doaj.org/article/eb6298dc37554341b4125173da4b9c27
Autor:
Alexandr Poprach, Anezka Zemankova, Igor Richter, Bohuslav Melichar, Hana Študentová, Aneta Rozsypalova, Tomas Buchler, Vladimir Samal, Josef Dvorak, Ondrej Brom, Jiri Bartos
Publikováno v:
Biomedical Papers. 166:97-104
Aim The aim of this study was to retrospectively analyze treatment outcomes and tolerance in patients in whom cabozantinib was used after previous targeted therapy. Patients and methods Cabozantinib was administered in dose 60 mg/day, a subset of pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c642cdf78a2446e03d6a284085472c25
https://doi.org/10.5507/bp.2020.055
https://doi.org/10.5507/bp.2020.055
Autor:
MARTINA SPISAROVA, BOHUSLAV MELICHAR, JARMILA JURANOVA, ANEZKA ZEMANKOVA, TOMAS ADAM, KATERINA MATOUSOVA, LENKA JAVORSKA, LENKA KUJOVSKA KRCMOVA, DOROTA TURONOVA, HANA STUDENTOVA
Publikováno v:
In Vivo
Background/Aim: Biomarkers that would identify patients unlikely to respond to immunotherapy with immune checkpoint inhibitors (ICIs) remain an unmet medical need. Patients and Methods: In the present study, we have retrospectively evaluated the asso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcad4b93551a3d314f352d860b75ae98
https://europepmc.org/articles/PMC9843774/
https://europepmc.org/articles/PMC9843774/
Autor:
Bohuslav Melichar, K Kikalova, Hana Študentová, J Havlasek, N Pastvova, Petr Mlejnek, Anezka Zemankova, Petr Dolezel
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:89-98
Lysosomal sequestration of weak base drugs has been identified as one of the stress-related mechanisms that trigger in vitro lysosomal biogenesis controlled by transcription factor EB (TFEB). Whether such mechanism can induce lysosomal biogenesis in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5b9c8129e351915b975b4ac6c1b5cf5
https://doi.org/10.1007/s00280-021-04266-6
https://doi.org/10.1007/s00280-021-04266-6
Autor:
Eva Streckova, Marie Kopecka, Bohuslav Melichar, Anezka Zemankova, Alexandr Poprach, Marketa Wiesnerova, Aneta Rozsypalova, Tomas Buchler, Igor Richter
Publikováno v:
Targeted Oncology. 15:673-679
Sarcopenia is common in advanced cancer and correlates with poor performance status, increased risk of treatment-related toxicity, and shortened survival. Inhibitors of the vascular endothelial growth factor pathway have been associated with developm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6de2f3768d0eca8560eb237613643f96
https://doi.org/10.1007/s11523-020-00744-8
https://doi.org/10.1007/s11523-020-00744-8
Autor:
Igor, Richter, Alexandr, Poprach, Anezka, Zemankova, Tomas, Buchler, Jiri, Bartos, Vladimir, Samal, Hana, Studentova, Aneta, Rozsypalova, Josef, Dvorak, Ondrej, Brom, Bohuslav, Melichar
Publikováno v:
Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 166(1)
The aim of this study was to retrospectively analyze treatment outcomes and tolerance in patients in whom cabozantinib was used after previous targeted therapy.Cabozantinib was administered in dose 60 mg/day, a subset of patients received initial dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6ada81c333d18e40aecd11750fedc3a3
https://pubmed.ncbi.nlm.nih.gov/33252116
https://pubmed.ncbi.nlm.nih.gov/33252116